Announcement PDF 1 AdAlta Limited (ASX:1AD) · ABN: 92 120 332 925 · www.adalta.com.au Suite 1.01, 117 Camberwell Road, Hawthorn East VIC 3123, Australia ASX Announcement | 14 July 2026 AdAlta Limited (ASX:1AD) AdAlta abstract selected for oral presentation at ISCT ANZ 2026 Recognition of AdAlta’s unique ‘East to West’ model for bringing groundbreaking cellular immunotherapies for cancer to patients worldwide Investment highlights • AdAlta’s abstract describing its ‘East to West’ business model was among the high-scoring submissions selected for oral presentation at ISCT ANZ 2026. • Selection recognises AdAlta’s differentiated, capital-efficient strategy for commercialising ground breaking solid tumour CAR-T therapies. Melbourne, Australia, 14 July 2026: AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next generation cellular immunotherapies for solid cancers, today announced that an abstract describing its “East to West” business model has been selected, on the basis of its high peer- review score, for oral presentation at the International Society for Cell & Gene Therapy (ISCT) ANZ 2026 Regional Meeting in Melbourne (20-22 July 2026). AdAlta’s abstract describes how its “East to West” business model brings promising Asian cell therapies to Western patients in a de-risked, capital efficient manner. The abstract features AdAlta’s collaboration with Shanghai Cell Therapy Group on lead product BZDS1901 (now known by AdAlta product code EW-001), a ground breaking CAR-T cell therapy that has demonstrated hard to achieve complete responses in advanced mesothelioma, a deadly cancer asspciated with asbestos expsoure. It also describes manufacturing collaborations with Cell Therapies Pty Ltd and Oribiotech that aim to deliver scalable, lower- cost CAR-T manufacturing across the Asia-Pacific. AdAlta CEO and Managing Director, Dr Tim Oldham said: “Being chosen for an oral presentation is independent validation that our ‘East to West’ model is genuinely novel and important. Connecting Asia’s remarkable cell therapy innovation with Australia’s world-class manufacturing and regulatory ecosystem is a credible, capital-efficient way to bring groundbreaking immunotherapies to cancer patients who currently have few options. We are proud to share this story with the region’s leading scientists, clinicians and developers.” Presentation details Meeting: ISCT ANZ 2026 Regional Meeting, Melbourne Convention and Exhibition Centre Title: “An East-to-West business model for commercialising solid tumour CAR-T therapies” Presenter: Dr Tim Oldham, CEO & Managing Director, AdAlta Oral Presentation Session: Monday, 20 July 2026, 8:00–9:00 am Poster Presentation: Monday, 20 July 2026, 6:00–8:00 pm; Tuesday, 21 July 2026, 6:00–7:00 pm More information: https://www.isctglobal.org/isctanz2026melbourne/home-2026 Next steps and strategic significance Recognition on this stage raises AdAlta’s profile among scientists, clinicians, regulators and potential partners central to executing its strategy, and reinforces the credibility of a replicable, capital-efficient model designed to create value across multiple products. AdAlta continues to advance manufacturing transfer, US FDA engagement and preparations for Australian Phase I development of EW-001 (BZDS1901). To view a summary, and engage in discussion about this announcement, visit AdAlta’s InvestorHub here: https://investorhub.adalta.com.au/link/Pbqg0r 2 This ASX announcement has been authorised for release by the CEO of AdAlta Limited (ASX:1AD). For further information, please contact: AdAlta Limited (ASX:1AD) Tim Oldham CEO & Managing Director P: +61 403 446 665 E: ir@adalta.com.au About EW-001 (formerly BZDS1901) EW-001 is a novel, first in class, CAR-T cell therapy designed to treat mesothelioma (a rare but rapidly fatal cancer usually linked to asbestos exposure) and with possible application in more than ten other cancers. CAR-T cell therapies are living drugs manufactured from a patient’s own immune cells that are engineered to be able to find and kill cancer. They offer the potential to provide durable cancer control or cure from a single treatment. Patients diagnosed with mesothelioma today are typically treated with surgery if possible and then initial or first line drug treatments are chemotherapy or immunotherapy. Once a patient has relapsed after initial therapy, second line treatment options are even more limited and outcomes are much poorer. Current treatments typically deliver: 1, 2 • Tumour shrinkage (Overall Response) in only 40-44% of first line patients and 11-29% of second and subsequent line patients • Complete tumour clearance (Complete Response) is rare and seen in less than 3% of first line patients and almost never in second line patients • Median survival (at which point 50% of patients will have died) often only 14-18 months first line and 8-10 months second line, with tumours beginning to grow again typically after only half that time. By contrast, EW-001 clinical studies in relapsed or advanced mesothelioma patients (second line and later) in China have reported: • Up to 50% Overall Response rate (tumour shrinkage) • Up to 20% Complete Response rate (complete tumour clearance) • Median overall survival has not yet been reached in the current study cohort, however an earlier generation of EW-001 achieved more than 25 months median survival These early results suggest EW-001 may offer an exciting potential new treatment option for patients with few alternatives. About AdAlta AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers. Through its ‘East to West’ strategy, the Company is integrating Asia's prowess in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients. AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization. AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model 1 CHECKMATE-743 study (nivolumab + ipilimumab against chemotherapy): S Peters et al, Annals of Oncology, 2022 (33) 488; https://doi.org/10.1016/j.annonc.2022.01.074 2 See for example CONFIRM study (nivolumab against placebo): DA Fennell et al, Lancet Oncol 2021 (22) 1530 3 delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products. Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US$20.3 billion by 2028. AdAlta’s first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering. To learn more, please visit: www.adalta.com.au For more information Join our InvestorHub Follow us on LinkedIn Follow us on X (formerly Twitter)